CorMedix Inc. (CRMD): R&D Expense
$19.33M
Year ended 2025-12-31
+21.9%
3-year compound annual growth
+7.6%
5-year compound annual growth
+11.9%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.33M | +390.4% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $3.94M | -70.0% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $13.16M | +23.2% | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | $10.68M | -18.7% | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | $13.13M | -1.8% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $13.38M | +21.0% | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | $11.05M | -41.3% | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | $18.82M | -23.1% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $24.49M | +55.6% | 2019-05-29, From 2017-01-01 |
| 2016-12-31 | $15.74M | +150.5% | 2018-03-19, From 2016-01-01 |
| 2015-12-31 | $6.28M | +376.4% | 2017-03-16, From 2015-01-01 |
| 2014-12-31 | $1.32M | +7.5% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $1.23M | +7.4% | 2015-03-12, From 2013-01-01 |
| 2012-12-31 | $1.14M | -71.8% | 2014-03-31, From 2012-01-01 |
| 2011-12-31 | $4.06M | -26.1% | 2014-03-04, From 2011-01-01 |
| 2010-12-31 | $5.49M | n/a | 2012-04-26, From 2010-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| CorMedix Inc. (CRMD) | 2025-12-31 | $19.33M | +390.4% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $9.58M | +4.4% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $95.14M | -14.6% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $31.16M | +21.9% |
| MannKind Corp (MNKD) | 2025-12-31 | $66.35M | +44.6% |
| Harrow, Inc. (HROW) | 2025-12-31 | $20.94M | +71.2% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $81.18M | +278.9% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $285.20M | -18.1% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $77.05M | +0.8% |
Compare CRMD, EOLS, IRWD, XERS side by side · Screen every company in Pharmaceutical Preparations ↗